Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

Inclusion Criteria:

Histological or cytological confirmation of advanced (inoperable stage III and stage IV) cutaneous or unknown primary melanoma
Tumor sample confirmed as BRAF mutation positive

Exclusion Criteria:

Diagnosis of uveal or mucosal melanoma
Any prior Investigational therapy comprising inhibitors of Ras, Raf or MEK
Having received an investigational drug within 30 days of starting treatment, or have not recovered from side effects of an investigational drug